Intelligence Report · ~15 min read
Sleep Disorders · Sleep-Disordered Breathing Therapeutic Area Assessment
6 signals · 2 insights · 14 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Low Confidence · 60%
Evidence
22 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Sleep Disorders · Sleep-Disordered Breathing integrates 6 signals, 2 executive insights, and 14 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 11, 2026
Study on Dopaminergic Pathway in Sleep Breathing Disorders Initiated
A clinical trial is underway to investigate the role of dopamine in sleep-disordered breathing using polysomnography and genetic testing.
View detail - signalJul 3, 2026
FDA Accepts Supplement Application for Ramelteon by Micro Labs
The FDA has accepted a supplemental application for Ramelteon submitted by Micro Labs.
View detail - signalJun 30, 2026
FDA Grants Approval for Ramelteon ANDA215485 by Hibrow Healthcare
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 215485 for Ramelteon submitted by Hibrow Healthcare.
View detail - signalJun 23, 2026
Study on Transcranial Electrostimulation for Pain Relief in OSA Surgery
A study is investigating the efficacy of transcranial electrostimulation (TES) for postoperative pain relief in obstructive sleep apnea surgery.
View detail - regulatoryJul 11, 2026
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pharmaceutical companies focusing on sleep disorders.
View detail - regulatoryJul 5, 2026
Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions to the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).
View detail - regulatoryJul 5, 2026
Real-World Evidence Submissions to the Center for Drug Evaluation and Research
As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions.
View detail - regulatoryJul 5, 2026
Clinical trials for medicines: modifying a clinical trial approval
Guidance on the various types of modifications that can be made to a clinical trial approval.
View detail - insightJul 4, 2026
Regulatory Milestone for Ramelteon Enhances Competitive Landscape in Sleep Disorders
The FDA's acceptance of the supplemental application for Ramelteon by Micro Labs is a significant regulatory milestone that could strengthen their market position in the sleep disorder therapeutic area. This development necessitates a strategic reassessment of competitive positioning for other companies in the sector. Regulatory context from FDA (FDA AP — RAMELTEON (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).
View detail - insightJun 30, 2026
New Ramelteon ANDA Approval Signals Increased Competition in Sleep Disorders Market
The FDA's approval of Ramelteon ANDA215485 by Hibrow Healthcare introduces a new competitor in the sleep disorder market, which could disrupt existing market dynamics. Portfolio teams need to evaluate the implications for pricing and market share of current therapies in this therapeutic area. Regulatory context from FDA (FDA AP — RAMELTEON (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (5 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 2 risk-calibrated assessments for portfolio review. 14 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
72%Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to pharmaceutical companies focusing on sleep disorders.
Source: FDA
View evidenceReal-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research
83%As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions to the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER).
Source: FDA
View evidenceReal-World Evidence Submissions to the Center for Drug Evaluation and Research
83%As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions.
Source: FDA
View evidenceClinical trials for medicines: modifying a clinical trial approval
83%Guidance on the various types of modifications that can be made to a clinical trial approval.
Source: MHRA
View evidenceFDA AP — TOFACITINIB CITRATE (ORIG)
77%Application ANDA209738. Sponsor: MICRO LABS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TOFACITINIB CITRATE.
Source: FDA
View evidenceFDA AP — TICAGRELOR (ORIG)
77%Application ANDA208539. Sponsor: MICRO LABS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: TICAGRELOR.
Source: FDA
View evidenceRegulatory Milestone for Ramelteon Enhances Competitive Landscape in Sleep Disorders
62%The FDA's acceptance of the supplemental application for Ramelteon by Micro Labs is a significant regulatory milestone that could strengthen their market position in the sleep disorder therapeutic area. This development necessitates a strategic reassessment of competitive positioning for other companies in the sector. Regulatory context from FDA (FDA AP — RAMELTEON (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).
Source: Humanexa Insight
View evidenceNew Ramelteon ANDA Approval Signals Increased Competition in Sleep Disorders Market
58%The FDA's approval of Ramelteon ANDA215485 by Hibrow Healthcare introduces a new competitor in the sleep disorder market, which could disrupt existing market dynamics. Portfolio teams need to evaluate the implications for pricing and market share of current therapies in this therapeutic area. Regulatory context from FDA (FDA AP — RAMELTEON (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (5 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Study on Dopaminergic Pathway in Sleep Breathing Disorders Initiated
Trial Update
- FDA Accepts Supplement Application for Ramelteon by Micro Labs
Regulatory Approval
- FDA Grants Approval for Ramelteon ANDA215485 by Hibrow Healthcare
Regulatory Approval
- Study on Transcranial Electrostimulation for Pain Relief in OSA Surgery
Trial Update
- Study on Sleep Quality Improvement with CPAP in Obstructive Sleep Apnea
Trial Update
- Real-World Study on Dong'e Brand Ejiao Yuanjiang for Sleep Improvement
Trial Update
Insights
- Regulatory Milestone for Ramelteon Enhances Competitive Landscape in Sleep Disorders
Sleep Disorders · Melatonin Receptor Agonist
- New Ramelteon ANDA Approval Signals Increased Competition in Sleep Disorders Market
Sleep Disorders · Melatonin Receptor Agonist